Association of AHSG Gene Polymorphisms With Fetuin-A Plasma Levels and Cardiovascular Diseases in the EPIC-Potsdam Study

Background— Elevated circulating levels of fetuin-A in blood have been associated with increased risk of cardiovascular disease. The goal of our study was to prospectively investigate the potential causal nature of the association between fetuin-A levels and myocardial infarction (MI) and ischemic stroke by applying a Mendelian randomization approach. Methods and Results— Five tagging single-nucleotide polymorphisms (rs2248690, rs2070633, rs2070635, rs4917, and rs6787344) capturing the common genetic variation of the fetuin-A coding gene α2-Heremans-Schmid glycoprotein (AHSG) were genotyped in a case-cohort comprising 214 MI cases, 154 ischemic stroke cases, and 2152 persons who remained free of cardiovascular disease events in the European Prospective Investigation into Cancer and Nutrition-Potsdam study. One single-nucleotide polymorphism (rs6787344) was discarded because of Hardy-Weinberg disequilibrium. All AHSG tagging single-nucleotide polymorphisms were associated with fetuin-A plasma levels (P<0.0001). AHSG rs4917 C>T showed the strongest association, explaining 21.2% of the phenotypic variance independent of potential confounding factors (+35.5 &mgr;g/mL increase per C-allele, P=2×10−121). Furthermore, the rs4917 C-allele showed a significant association with MI (adjusted hazard rate ratio [RR] 1.34, 95% CI 1.05 to 1.70, P=0.02). Based on this association, the expected RR for MI corresponding to 1 SD in fetuin-A was 1.54 and, thus, strikingly matches the previously observed association between fetuin-A plasma levels and MI risk (RR 1.59). Conclusions— These data provide evidence for the causal nature of the recently reported association between fetuin-A plasma levels and MI risk, thereby suggesting an involvement of fetuin-A in the pathogenesis of cardiovascular disease.

[1]  M. Olivier.  A haplotype map of the human genome , 2003, Nature.

[2]  P. Stenvinkel,et al.  Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin-A in chronic kidney disease. , 2008, Advances in clinical chemistry.

[3]  W. Tian,et al.  Association of α2-HS glycoprotein (AHSG, fetuin-A) polymorphism with AHSG and phosphate serum levels , 2005, Human Genetics.

[4]  H. Boeing,et al.  Follow-Up Procedures in EPIC-Germany – Data Quality Aspects , 1999, Annals of Nutrition and Metabolism.

[5]  H. Boeing,et al.  Recruitment Procedures of EPIC-Germany , 1999, Annals of Nutrition and Metabolism.

[6]  K. Burgdorf,et al.  AHSG Tag Single Nucleotide Polymorphisms Associate With Type 2 Diabetes and Dyslipidemia , 2008, Diabetes.

[7]  R. Mangiafico,et al.  Association of high alpha2-Heremans-Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. , 2007, Atherosclerosis.

[8]  H. Tunstall-Pedoe,et al.  Myocardial Infarction and Coronary Deaths in the World Health Organization MONICA Project: Registration Procedures, Event Rates, and Case‐Fatality Rates in 38 Populations From 21 Countries in Four Continents , 1994, Circulation.

[9]  P. Stenvinkel,et al.  Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. , 2005, Kidney international.

[10]  M. Shlipak,et al.  Association Between Human Fetuin-A and the Metabolic Syndrome: Data From the Heart and Soul Study , 2006, Circulation.

[11]  J. Hirschhorn,et al.  CCL2 Polymorphisms Are Associated With Serum Monocyte Chemoattractant Protein-1 Levels and Myocardial Infarction in the Framingham Heart Study , 2005, Circulation.

[12]  M. Haasemann,et al.  The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. , 1992, European journal of biochemistry.

[13]  P. Froguel,et al.  A synonymous coding polymorphism in the alpha2-Heremans-schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. , 2005, Diabetes.

[14]  Y. Ikeda,et al.  A promoter polymorphism of the alpha2-HS glycoprotein gene is associated with its transcriptional activity. , 2008, Diabetes research and clinical practice.

[15]  M. Schulze,et al.  Plasma Fetuin-A Levels and the Risk of Myocardial Infarction and Ischemic Stroke , 2008, Circulation.

[16]  S. Gabriel,et al.  Efficiency and power in genetic association studies , 2005, Nature Genetics.

[17]  Peter H. Westfall,et al.  Testing Association of Statistically Inferred Haplotypes with Discrete and Continuous Traits in Samples of Unrelated Individuals , 2002, Human Heredity.

[18]  Wj Gauderman,et al.  QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies , 2006 .

[19]  R. L. Prentice,et al.  A case-cohort design for epidemiologic cohort studies and disease prevention trials , 1986 .

[20]  M. Schulze,et al.  Plasma Fetuin-A Levels and the Risk of Type 2 Diabetes , 2008, Diabetes.

[21]  N. Risch,et al.  A comparison of linkage disequilibrium measures for fine-scale mapping. , 1995, Genomics.

[22]  H. Boeing,et al.  Recruitment procedures of EPIC-Germany. European Investigation into Cancer and Nutrition. , 1999, Annals of nutrition & metabolism.

[23]  F. Schick,et al.  AHSG gene variation is not associated with regional body fat distribution--a magnetic resonance study. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[24]  A. Schwarz,et al.  The serum protein α2–Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification , 2003 .

[25]  K. Berger,et al.  Joint effects of risk factors for stroke and transient ischemic attack in a German population , 2007, Journal of Neurology.

[26]  M. Schulze,et al.  A statistical test for the equality of differently adjusted incidence rate ratios. , 2007, American journal of epidemiology.

[27]  Annemarie Koster,et al.  Fetuin-A and incident diabetes mellitus in older persons. , 2008, JAMA.

[28]  G. Pagès,et al.  Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity , 1989, Cell.

[29]  Y. Ikeda,et al.  A promoter polymorphism of the α2-HS glycoprotein gene is associated with its transcriptional activity , 2008 .

[30]  M. Olivier.  A haplotype map of the human genome. , 2003, Nature.

[31]  W. Jahnen-Dechent,et al.  Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. , 2003, The Biochemical journal.

[32]  H. Boeing,et al.  Measures of Quality Control in the German Component of the EPIC Study , 1999, Annals of Nutrition and Metabolism.

[33]  H Boeing,et al.  Validation of a self-administered food-frequency questionnaire administered in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study: comparison of energy, protein, and macronutrient intakes estimated with the doubly labeled water, urinary nitrogen, and repeated 24-h dietary , 1999, The American journal of clinical nutrition.

[34]  H. Koyama,et al.  Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. , 2006, Diabetes care.

[35]  G. Grunberger,et al.  α2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor , 2000, Molecular and Cellular Endocrinology.

[36]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[37]  Paolo Vineis,et al.  Design Options for Molecular Epidemiology Research within Cohort Studies , 2005, Cancer Epidemiology Biomarkers & Prevention.

[38]  F. Schick,et al.  α2-Heremans-Schmid Glycoprotein/ Fetuin-A Is Associated With Insulin Resistance and Fat Accumulation in the Liver in Humans , 2006 .

[39]  N. Stefan,et al.  Fetuin-A Induces Cytokine Expression and Suppresses Adiponectin Production , 2008, PloS one.

[40]  D. Levy,et al.  Contribution of Clinical Correlates and 13 C-Reactive Protein Gene Polymorphisms to Interindividual Variability in Serum C-Reactive Protein Level , 2006, Circulation.

[41]  D. Levy,et al.  Comprehensive Survey of Common Genetic Variation at the Plasminogen Activator Inhibitor-1 Locus and Relations to Circulating Plasminogen Activator Inhibitor-1 Levels , 2005, Circulation.

[42]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[43]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[44]  Keith R Abrams,et al.  An integrated approach to the meta-analysis of genetic association studies using Mendelian randomization. , 2004, American journal of epidemiology.

[45]  T. Reinehr,et al.  Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. , 2008, The Journal of clinical endocrinology and metabolism.